The WHO AWaRe Antibiotic Book: providing guidance on optimal use and informing policy

Abstract

MS reports grants from: (1) the ADILA project (Antimicrobial Resistance, Prescribing, and Consumption Data to Inform Country Antibiotic Guidance and Local Action; funder, Wellcome Trust; grant holder, St Georges; April, 2022–October, 2025); (2) Impact of oral step-down to amoxicillin or co-amoxiclav and of duration of antibiotic therapy on effectiveness, safety and selection of antibiotic resistance in severe childhood community-acquired pneumonia (CAP): a randomised controlled trial (PediCAP; funder, EDCTP; grant holder, PENTA; April 2014–March, 2024; and (3) NeoAMR Global Neonatal Sepsis Observational Study (NeoOBS): a prospective cohort study of sepsis in hospitalised neonates (funder, DNDi; grant holder, GARDP; September, 2017–August, 2024, (€1 826 618 total) – Chief Investigator (5%). MS also reports roles as Member of the WHO Essential Medicines List (EML) Committee (from 2016) and Chair of the EML Antibiotic Working Group (from 2019). ML reports participation on advisory boards for Sunovion pharmaceuticals (payment for advisory board on pneumonia) and Paladin Labs (payment for advisory board on dalbavancin). He also reports payments to him, and McMaster University made by the WHO EML team. SH reports grants paid by the European Commission to his institution (University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland). CP reports that she currently works for the French Ministry of Health, coordinating the Antimicrobial Resistance National Action Plan. All other authors declare no competing interests.